DexCom, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jacob S. Leach
- Full Time Employees
- 11,100
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 6340 Sequence Drive San Diego CA United States 92121
- IPO Date
- Apr 14, 2005
- CIK
- 0001093557
- Website
- dexcom.com
- Similar Companies
- Business
- DexCom, Inc. is a leading medical technology firm dedicated to the engineering, production, and worldwide distribution of continuous glucose monitoring (CGM) solutions. The company's innovative systems are utilized by individuals managing diabetes, as well as by healthcare professionals, to facilitate enhanced glucose management. Its portfolio includes the sophisticated Dexcom G7 system, noted for its compact design, rapid warm-up, and all-in-one sensor with integrated transmitter, which stands as the most accurate CGM available and offers direct connectivity to smartwatches. Dexcom also provides the reliable Dexcom G6, an integrated CGM system, and the simplified Dexcom ONE, aimed at replacing routine fingerstick blood glucose testing for treatment decisions. Expanding its reach, Dexcom launched the Stelo Glucose Biosensor System in 2024, offering an over-the-counter CGM option for adults not on insulin, focusing on metabolic health and lifestyle insights. The company further empowers users with Dexcom Share, a remote monitoring feature, and the Dexcom Real-Time API, enabling third-party developers to integrate live CGM data into various digital health applications. Additionally, Dexcom Clarity provides a cloud-based platform for glucose trend analysis and reporting for both users and healthcare providers. In recent developments, Dexcom received FDA clearance in November 2025 for Dexcom Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 long-acting insulin, slated for a December 2025 launch alongside an extended 15-day G7 sensor. Dexcom actively pursues partnerships, including collaborations with insulin pump manufacturers and digital health platforms to expand system compatibility. Founded in 1999, DexCom, Inc. is headquartered in San Diego, California, and maintains a global presence.
Company News
DexCom to Launch 15-Day G7 CGM System in Canada This November
Dexcom Invites the Global Diabetes Community to Share Their Stories Through A Letter to Diabetes Campaign
DexCom: Improving Patient Access Makes It A Long-Term Buy
DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise
DexCom, Inc. (DXCM) Q3 2026 Earnings Call Transcript
What DexCom (DXCM) Said on Its Q3 Earnings Call
DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates
DexCom Q3 2026 Earnings Call Transcript
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
Diabetes Wearable-Maker Handily Beats Earnings Views, Hikes Sales Guide
Dexcom Reports Third Quarter 2026 Financial Results
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
DexCom Gears Up to Report Q3 Results: How to Play the Stock?
DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors
DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study
DexCom (NASDAQ:DXCM) EVP Michael Jon Brown Sells 1,700 Shares of Company Stock
DexCom: The 15-Day Sensor Lowered The Cost Curve Before The Type 2 Wave Arrives
Glucose monitoring devices for type 2 diabetes benefit even those not on insulin
Health Rounds: Glucose monitoring devices for type 2 diabetes benefit even those not on insulin